<DOC>
	<DOCNO>NCT03083873</DOCNO>
	<brief_summary>Prospective , multicenter , single-arm , open label , interventional study evaluate adoptive cell therapy ( ACT ) autologous tumor infiltrate lymphocyte ( TIL ) infusion ( LN-145 ) follow IL-2 non-myeloablative ( NMA ) lymphodepletion preparative regimen treatment patient recurrent and/or metastatic squamous cell carcinoma head neck</brief_summary>
	<brief_title>Study LN-145 Autologous Tumor Infiltrating Lymphocytes Treatment Squamous Cell Carcinoma Head &amp; Neck</brief_title>
	<detailed_description>LN-145 adoptive cell transfer therapy utilize autologous TIL manufacturing process , originally develop NCI , treatment patient recurrent and/or metastatic squamous cell carcinoma head neck . The cell transfer therapy use study involve patient receive NMA lymphocyte deplete preparative regimen , follow infusion autologous TIL follow administration regimen IL-2 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Must great 18 year age time consent . Must persistent , recurrent metastatic HNSCC ; histologic documentation primary tumor require via pathology report . Must least 1 prior systemic chemotherapeutic regimen management persistent , recurrent metastatic HNSCC . Patients must curative therapy option , intolerant , decline standard care therapy persistent , recurrent metastatic disease . Any prior therapy direct malignant tumor , include radiation therapy , chemotherapy , biologic/targeted agent immunologic agent must discontinue least 21 day prior tumor resection prepare TIL therapy . Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Patients must seronegative HIV antibody , hepatitis B antigen , hepatitis C antibody antigen . Female patient childbearing potential must willing practice approve method birth control start time inform consent 1 year completion lymphodepletion regimen . Patients systemic steroid therapy ( great 10 mg prednisone equivalent ) within 28 day prior Visit 2 . Patients currently prior therapyrelated toxicity great Grade 1 accord Common Toxicity Criteria Adverse Events ( CTCAE ) v4.03 ; ( see Appendix Section 16.4 ) , except alopecia vitiligo prior enrollment . Patients immunotherapyattributable AE : lead discontinuation , ophthalmologic neurologic AE grade , actively receive immunosuppressive agent treatment toxicity relate prior immunotherapy . Patients document Grade 2 great diarrhea colitis result previous immunotherapy within six month screen . History severe immediate hypersensitivity reaction cyclophosphamide , fludarabine , IL2 . Patients active systemic infection , coagulation disorder active major medical illness cardiovascular , respiratory immune system . Have form primary immunodeficiency , severe combine immunodeficiency disease acquire immune deficiency syndrome ( AIDS ) . Diagnosis endstage renal disorder require hemodialysis . Patients leave ventricular ejection fraction ( LVEF ) &lt; 45 % . Patients FEV1 ( forced expiratory volume one second ) less equal 60 % normal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>LN-145</keyword>
	<keyword>Cell Therapy</keyword>
	<keyword>Autologous Adoptive Cell Transfer</keyword>
	<keyword>Autologous Adoptive Cell Therapy</keyword>
	<keyword>Cellular Immuno-therapy</keyword>
	<keyword>Tumor Infiltrating Lymphocytes</keyword>
	<keyword>TIL</keyword>
	<keyword>IL-2</keyword>
</DOC>